REGENXBIO Unveils Presentations at Gene Therapy Meeting
REGENXBIO Inc. (Nasdaq: RGNX) has exciting news as they prepare for the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting. This event showcases their extensive capabilities in research, clinical development, and manufacturing within the gene therapy space.
Key Presentations Scheduled
Among the presentations are updates from late-stage clinical trials for promising gene therapies such as RGX-121, a treatment aimed at MPS II, and RGX-202 for Duchenne muscular dystrophy. They will also share insightful preclinical research highlighting the innovative design of RGX-202.
Oral Presentations to Highlight Innovations
The event will feature several key oral presentations, offering a platform for REGENXBIO's leaders to present their findings:
- Development of a Commercial Manufacturing Process for RGX-202 - Presented by Donald Startt, this session focuses on the advancements in the manufacturing process tailored for this treatment.
- RGX-121: A Gene Therapy for MPS II - Olivier Danos, Ph.D., will share insights into the investigational gene therapy designed to address this rare condition.
- RGX-202 Interim Clinical Data - Also presented by Dr. Danos, this session will cover the interim findings from ongoing trials for Duchenne muscular dystrophy.
Poster Presentations Showcasing Research
In addition to oral presentations, REGENXBIO will present a series of research posters.
- Impact of Sample Collection on Testing - Amanda Zhang's presentation will delve into how different variables affect the accuracy of testing for adeno-associated viruses.
- AAV-Expressed Microdystrophin in Duchenne Models - Benjamin Heithoff will discuss how this innovative approach improves muscle function in models of Duchenne muscular dystrophy.
- Oversized AAV Vectors Characterization - Randolph Qian will share findings on how these vectors can enhance therapeutic outcomes.
About REGENXBIO Inc.
REGENXBIO is on a mission to harness the power of gene therapy to improve patient lives. Since its inception, the company has led advancements in AAV gene therapy and is currently developing treatments for rare diseases. Their pipeline features therapies like RGX-202 and RGX-121, both of which represent significant advancements in gene delivery methods. Additionally, REGENXBIO’s partnership with esteemed organizations has driven the development and commercialization of cutting-edge therapies aimed at conditions that presently have limited treatment options.
With thousands of patients already impacted through their innovative treatments, REGENXBIO exemplifies the promise of gene therapy. Their collaboration with major industry players underlines their commitment to transforming healthcare for individuals facing challenging health conditions.
Frequently Asked Questions
What is the focus of REGENXBIO's presentations at ASGCT?
REGENXBIO will present data from clinical trials of RGX-121 and RGX-202, showcasing advancements in gene therapy for rare diseases.
Who is leading the presentations for REGENXBIO?
Several key figures, including Donald Startt and Olivier Danos, Ph.D., will present their findings at the ASGCT meeting.
How long has REGENXBIO been in operation?
REGENXBIO was founded in 2009 and has been at the forefront of gene therapy innovations since its inception.
What diseases are targeted by REGENXBIO's therapies?
The company is primarily focused on rare diseases, including Duchenne muscular dystrophy and mucopolysaccharidosis type II.
What is the significance of AAV technology for REGENXBIO?
AAV technology is a cornerstone of REGENXBIO's gene therapies, as it offers a robust method for delivering genes directly to target cells in patients.
